Telbivudine or Tenofovir Treatment in HBeAg-negative Chronic Hepatitis B Patients Based on the Roadmap Concept
Status:
Completed
Trial end date:
2015-12-10
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the efficacy and safety following the Roadmap
Concept strategy with an initial monotherapy using either telbivudine or tenofovir in HBeAg
negative CHB patients. The data from the study should allow for the validation of the Roadmap
concept in a prospective manner, for both telbivudine and tenofovir treated HBeAg negative
CHB patients. As part of a post-approval commitment to the European Health Authorities, the
data will also be used to provide an optimized clinical treatment strategy for better
clinical use of telbivudine in European HBeAg negative patients. Furthermore, the data from
the study will contribute to a better scientific understanding, disease management and
treatment of HBeAg negative CHB patients.